Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8HE8

Human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor

Summary for 8HE8
Entry DOI10.2210/pdb8he8/pdb
DescriptorPoly [ADP-ribose] polymerase 2, GLYCEROL, 1-[[4-fluoranyl-3-(3-oxidanylidene-4-pentan-3-yl-piperazin-1-yl)carbonyl-phenyl]methyl]quinazoline-2,4-dione, ... (4 entities in total)
Functional Keywordsparp-2, dna adp-ribosyltransferase, inhibitor, transferase
Biological sourceHomo sapiens (human)
Total number of polymer chains3
Total formula weight121018.93
Authors
Wang, X.Y.,Xu, B.L.,Zhou, J. (deposition date: 2022-11-07, release date: 2023-11-08)
Primary citationZhou, J.,Du, T.,Wang, X.,Yao, H.,Deng, J.,Li, Y.,Chen, X.,Sheng, L.,Ji, M.,Xu, B.
Discovery of Quinazoline-2,4(1 H ,3 H )-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis.
J.Med.Chem., 66:14095-14115, 2023
Cited by
PubMed Abstract: PARP-1/2 inhibitors have become an important therapeutic strategy for the treatment of HR-deficient tumors. However, discovery of new inhibitors with an improved and distinct pharmacological file still need enormous explorations. Herein, a series of novel highly potent PARP-1/2 inhibitors bearing an -substituted piperazinone moiety were achieved. In particular, was identified as a distinct PARP inhibitor, showing remarkable enzymatic activity not only toward PARP-1 (IC = 0.94 nM) and PARP-2 (IC = 0.87 nM) but also toward PARP-7 (IC = 0.21 nM), as well as high selectivity over other PARP isoforms. Furthermore, was orally bioavailable and significantly repressed the tumor growth in both breast cancer and prostate cancer xenograft model. The crystal structures of within PARP-1 and PARP-2 together with the predicted binding mode within PARP-7 revealed its binding features and provided insightful information for further developing highly potent and selective PARP-1 and/or PARP-7 inhibitors.
PubMed: 37843892
DOI: 10.1021/acs.jmedchem.3c01152
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.05 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon